Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15923520 | 0.95 | ALDH1A1 (0.67) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL9168088 | 0.95 | ALDH1A1 (0.67) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL9170322 | 0.95 | ALDH1A1 (0.67) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL656530 | 0.92 | ALDH1A1 (0.71) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL9492603 | 0.90 | ALDH1A1 (0.76) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL10971124 | 0.86 | ALDH1A1 (0.70) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL5506840 | 0.85 | PKM (0.63) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL8884550 | 0.85 | ATM (0.67) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL4488519 | 0.85 | ALDH1A1 (0.66) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL5149346 | 0.85 | ALDH1A1 (0.69) | ALDH1A1HPGDSMN1; SMN2POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2004-12-30 | — | — | US | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| CN-1073552-C | Benzamides for neurodegenerative disorder treatment | CENTAUR PHARMACEUTICALS INC (US) | 2001-10-24 | — | — | CN | claimed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | claimed |
| US-5914350-A | TREATING PARKINSON*S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | claimed |
| US-5907061-A | AMIDATION A NITROBENZOYLHALIDE WITH A SATURATED ALKYLAMINE TO FORM A DRUG TREATING PARKINSON'S DISEASE OR SLOW THE PROGRESSIVE LOSS OF FUNCTION | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-05-25 | — | — | US | claimed |
| CN-1182416-A | Benzamides for neurodegenerative disorder treatment | CENTAUR PHARMACUETICALS INC (US) | 1998-05-20 | — | — | CN | claimed |
| EP-0819113-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | claimed |
| US-5659082-A | Nitro- and aminobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | claimed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | claimed |
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | disclosed |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2006-05-11 | — | — | US | disclosed |
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-5643965-A | TREATMENT OF DOPAMINE ASSOCIATED NERVOUS SYSTEM DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
| CN-1132505-A | Amidine derivatives with nitric oxide synthetase activities | ASTERA CO (SE) | 1996-10-02 | — | — | CN | disclosed |
| US-4218378-A | 11a-Methano-TXA compounds | THE UPJOHN COMPANY (US) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | ALDH1A1 1065/4885HPGD 582/4885SMN1; SMN2 8/4885 |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | ALDH1A1 1065/4885HPGD 582/4885SMN1; SMN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.